---
title: "Lysergide (DT120) in Generalized anxiety disorder: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Humanistic burden and health-related quality of life. Topics: Health-related quality of life by GAD symptom severity: 2022 US National Health and Wellness Survey, Health-related quality of life in likely undiagnosed and diagnosed GAD: 2022 US National Health and Wellness Survey, Degree of impairment among U.S. adults with past-year GAD, Functional impairment and health-related quality of life: systematic review of studies in North America and Europe, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Health-related quality of life by GAD symptom severity: 2022 US National Health and Wellness Survey

> “This cross-sectional study analyzed data from the 2022 US National Health and Wellness Survey, a nationally-representative, online-based survey.”
> “Adjusted EQ-5D index scores were significantly lower among mild (0.80, 95% confidence interval [CI]: 0.79-0.81), moderate (0.75, 95%CI: 0.74-0.76), and severe GAD (0.66, 95%CI: 0.65-0.67) than controls (0.84, 95%CI: 0.84-0.84), with scores decreasing as severity worsened.”
> “Compared with controls (45.3, 95%CI: 45.2-45.4), adjusted GHC scores were significantly lower among mild (41.5, 95%CI: 41.0-42.0), moderate (38.3, 95%CI: 37.8-38.9), and severe GAD (35.0, 95%CI: 34.4-35.6), with scores decreasing as severity worsened, and significantly higher among diagnosed patients with no GAD symptoms (46.8, 95%CI: 46.1-47.4).”
> “A similar trend was observed for MHC and PHC scores, but the magnitude of difference for PHC was smaller, suggesting a greater impact of GAD symptom severity on mental health functioning than physical health functioning.”

Source: [Duong et al. (2024a)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/137867)

<a id="topic-2.2.1.8.1-2"></a>

### Health-related quality of life in likely undiagnosed and diagnosed GAD: 2022 US National Health and Wellness Survey

> “A retrospective, cross-sectional observational study was conducted using data from the 2022 US National Health and Wellness Survey (N = 75,261 adults).”
> “Adults with likely GAD experienced significantly lower HRQoL, greater work productivity loss, activity impairment, emergency room visits, hospitalizations, and healthcare costs (both direct and indirect), than those with diagnosed GAD.”
> “Adults with GAD-whether likely and undiagnosed or diagnosed-had significantly lower HRQoL and higher work productivity loss, activity impairment, healthcare resource use, and healthcare costs than those without GAD.”

Source: [Duong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41519172/)

<a id="topic-2.2.1.8.1-3"></a>

### Degree of impairment among U.S. adults with past-year GAD

> “Of adults with generalized anxiety disorder in the past year, degree of impairment ranged from mild to serious, as shown in Figure 2. Impairment was determined by scores on the Sheehan Disability Scale.”
> “An estimated 32.3% had serious impairment, 44.6% had moderate impairment, and 23.1% had mild impairment.”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.8.1-4"></a>

### Functional impairment and health-related quality of life: systematic review of studies in North America and Europe

> “GAD was associated with increased impairments in psychosocial functioning, role functioning, work productivity and health-related quality of life (HRQL).”
> “The HRQL impairments were comparable with those associated with depression or panic disorder.”
> “Patients with GAD and co-morbid depression reported significantly greater impairment in HRQL than did those with either disorder alone.”

Source: [Revicki et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22154706/)

<a id="topic-2.2.1.8.1-5"></a>

### Role functioning and quality of life compared with other mental disorders: review of 34 studies

> “A review of 34 studies reporting original quantitative data on associations between GAD and role functioning, QOL, and/or economic costs was undertaken.”
> “Large representative studies showed that role impairments of pure GAD were similar in magnitude to those of pure MDD.”
> “Studies of DSM-IV disorders showed that QOL impairments of GAD were at least comparable in magnitude to those of MDD; studies of DSM-III-R disorders showed the opposite pattern.”

Source: [Hoffman et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17146763/)

<a id="topic-2.2.1.8.1-6"></a>

### Quality of life in anxiety disorders compared with nonclinical controls: meta-analysis

> “Thirty-two patient samples from 23 separate studies (N=2892) were included in the analysis. The results yielded a large effect size indicating poorer quality of life among anxiety disorder patients vs. controls and this effect was observed across all anxiety disorders.”
> “QOL domains of mental health and social functioning were associated with the highest levels of impairment among anxiety disorder patients.”

Source: [Olatunji et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17343963/)

<a id="topic-2.2.1.8.1-7"></a>

### Impairment in U.S. primary care patients with anxiety disorders

> “Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder, 6.8% (CI, 5.3% to 8.6%) had a panic disorder, and 6.2% (CI, 4.7% to 7.9%) had a social anxiety disorder.”
> “Each disorder was associated with substantial impairment that increased significantly (P < 0.001) as the number of anxiety disorders increased.”
> “Many patients (41%) with an anxiety disorder reported no current treatment.”

Source: [Kroenke et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17339617/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
